Treatment of anemia in Chronic Kidney Disease (CKD), a problem of public health proportions, involves utilization of invasive and costly treatment options. Moreover, recent clinical trials have revealed several complications arising from the use of erythropoiesis stimulating agents in the treatment of anemia of CKD. There is an unmet need for safer, cheaper and effective treatment options for anemia of CKD.
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Anemia is a common complication of Chronic Kidney Disease (CKD) [1] . Traditionally, the use of Erythropoiesis Stimulating Agents (ESAs), iron infusions and blood transfusions are considered to be the cornerstone therapeutics for the treatment of anemia of CKD. However, these treatment options are not only costly and invasive, use of ESAs has been recently linked to adverse events and poor outcomes in several large scale randomized clinical trials in the CKD population [2] [3] [4] . This has recently shifted the focus on finding newer therapeutics that are safer, cost effective and efficacious. Over the last decade, the research in this direction has gained momentum due to the discovery of hepcidin, a novel 25 amino-acid peptide, which is now believed to be the master regulator of iron homeostasis in health and disease [5] .
Hepcidin controls iron trafficking in the body by binding to ferroportin-a transmembrane iron channel [6] . Since ferroportin is the only known exit route for intracellular iron, hepcidin blocks cellular iron exit by binding to ferroportin and promoting its degradation and internalization [6] . Thus, by binding to ferroportin on the basolateral membrane of the duodenal enterocytes and on the cell membrane of the reticuloendothelial cells, hepcidin reduces iron absorption and iron release from macrophages, respectively. This leads to decreased iron bio-availability and iron restriction. Since, hepcidin levels are known to be elevated in CKD, [7] hepcidin is now believed to play a central role in mediation of anemia of CKD by reducing iron bio-availability and promoting iron restricted erythropoiesis [8] . Animal studies have demonstrated improvement in iron availability by lowing hepcidin using anti-hepcidin antibodies, providing evidence to suggest that targeting elevated hepcidin in CKD could potentially ameliorate anemia of CKD [9] .
In our quest to develop effective anti-hepcidin therapeutics, identifying the reversible underlying causes leading to elevated hepcidin levels in CKD is of paramount importance. In individuals with CKD, hepcidin levels could be elevated due to several reasons of which decreased renal clearance (reduced glomerular filtration rate) is thought to be the primary mechanism. Other possible mechanisms include increase in inflammatory cytokines in CKD and regular iron therapy which stimulate hepcidin synthesis [10] . Several studies have now shown that the factors described above explain only part of the variability of hepcidin concentrations in CKD, indicating that other factors likely play a role in stimulating hepcidin production in CKD [7, 11, 12] . Over the last few years, vitamin D deficiency, which is highly prevalent in CKD, has emerged as a putative factor contributing towards development hepcidin excess in CKD.
A recent cell-line study showed that vitamin D directly inhibits hepcidin transcription in hepatocytes by direct transcriptional suppression of the hepcidin gene leading to decreased hepcidin synthesis [13] . A pilot study in healthy human volunteers showed a 34% decrease in hepcidin levels within 24 hours after a single large dose of 25D-hydroxy vitamin D [13] . Along the same lines, another study in individuals with CKD revealed an inverse association between change in vitamin
